Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

PartnershipLumipodlinTAGRISSOPositive

AI Analysis

Summary

Abbisko Therapeutics and AstraZeneca announced a strategic collaboration to conduct clinical trials of Lumipodlin (ABSK043), a first-in-class oral PD-L1 inhibitor, in combination with TAGRISSO for NSCLC treatment.

Clinical Trial Data

Importance:7/10

Sentiment:

0.60

partnershipclinical_trialcombination_therapyoncologyNSCLCPD-L1_inhibitor

Related Companies

$AZN

Read the original article

Published by yahoo_finance on July 2, 2026 1:00 AM

Read Original